DrugMapper


Trade Names:	CECLOR CECLOR CD CEFACLOR RANICLOR
Synonyms:	BACTICLOR MR CECLOR CECLOR CD CEFACLOR MONOHYDRATE COMPOUND 99638 COMPOUND-99638 DISTACLOR DISTACLOR MR J01DC04 KEFTID NSC-757422 RANICLOR
Status:	Approved (1979)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	J01DC04
UNII:	69K7K19H4L


InChI Key	QYIYFLOTGYLRGG-GPCCPHFNSA-N
Smile	N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1
InChI	InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H14ClN3O4S
Molecular Weight	367.81
AlogP	0.62
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	4.0
Polar Surface Area	112.73
Molecular species	ACID
Aromatic Rings	1.0
Heavy Atoms	24.0

Action	Mechanism of Action	Reference
INHIBITOR	Bacterial penicillin-binding protein inhibitor

Mesh Heading	Maximum Phase	Mesh ID	Reference
Osteomyelitis	1	D010019	ClinicalTrials

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Nervous system disorders Headache	5.44
Gastrointestinal disorders Abdominal pain	4.67
Gastrointestinal disorders Gastrointestinal pain	4.67
Gastrointestinal disorders Diarrhoea	4.08
Gastrointestinal disorders Abdominal pain	3.4
Gastrointestinal disorders Diarrhoea	3.4
Gastrointestinal disorders Gastrointestinal pain	3.4
General disorders and administration site conditions Asthenia	3.33
Nervous system disorders Headache	3.2
Gastrointestinal disorders Diarrhoea	2.67
Nervous system disorders Headache	2.67
Gastrointestinal disorders Nausea	2.5
Infections and infestations Vulvovaginal candidiasis	2.5
Infections and infestations Vulvovaginal mycotic infection	2.5
Respiratory, thoracic and mediastinal disorders Epistaxis	2.04
General disorders and administration site conditions Pain	2.04
Infections and infestations Vaginal infection	2.0
Vaginal inflammation	2.0
Infections and infestations Vaginal infection	1.7
Vaginal inflammation	1.7
General disorders and administration site conditions Asthenia	1.36
Infections and infestations Vaginal infection	1.36
Vaginal inflammation	1.36
General disorders and administration site conditions Pain	0.667
General disorders and administration site conditions Serum sickness-like reaction	0.03

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Immune system disorders	29.25
Skin and subcutaneous tissue disorders	14.53
General disorders and administration site conditions	9.69
Gastrointestinal disorders	7.98
Vascular disorders	6.08
Nervous system disorders	5.22
Respiratory, thoracic and mediastinal disorders	4.37
Infections and infestations	3.8
Injury, poisoning and procedural complications	3.23
Investigations	3.23
Musculoskeletal and connective tissue disorders	2.28

Cross References

Resources	Reference
ChEBI	3478
ChEMBL	CHEMBL680
DrugBank	DB00833
DrugCentral	525
EPA CompTox	DTXSID3022748
FDA SRS	69K7K19H4L
Human Metabolome Database	HMDB14971
KEGG	C06877
PDB	8XI
PubChem	7048572
SureChEMBL	SCHEMBL33540
ZINC	ZINC000003812869
ChEBI	3478
ChEMBL	CHEMBL1201018
DrugBank	DB00833
FDA SRS	69K7K19H4L
Human Metabolome Database	HMDB14971
PDB	8XI
PubChem	7048572
SureChEMBL	SCHEMBL33540

CEFACLOR

Structure

Physicochemical Descriptors

Pharmacology

Indications

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70